Overview

Pharmacodynamics and Arteriovenous Differences of Naloxone in Healthy Participants Exposed to an Opioid

Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Overdose with potential deadly outcome is a serious problem among opioid abusers, not least in Norway. To save lives, immediate treatment with a μ-opioid antidote such as naloxone is required. The purpose of this study is to explore the pharmacokinetics and pharmacodynamics of naloxone in healthy volunteers under opioid influence.
Phase:
N/A
Details
Lead Sponsor:
Norwegian University of Science and Technology
Collaborator:
St. Olavs Hospital
Treatments:
Analgesics, Opioid
Naloxone
Remifentanil